CLDN18.2-targeted CAR-NK cells suppress gastric cancer growth in preclinical models.
Preclinical proof-of-concept for a rationally designed CAR4-NK therapy against CLDN18.2-positive gastric cancer, in which CD28H-2B4 co-stimulatory domains enhance the effector function of CAR4-NK cells, and show the potential of irradiated CAR4-NK cells as a safer, controllable "off-the-shelf" product candidate.